Safety

MP1032’s first-in-class, self-regulating mechanism translates into an excellent safety profile, as demonstrated in three Phase IIa studies with 234 treated patients. Dose-limiting toxicity could never be reached in preclinical in vivo models:

In a randomized phase IIa psoriasis study with 155 patients, treatment-emergent adverse events (TEAEs) occurred less frequently in both treatment groups than in the placebo group, depending on the dose:

For more information on MP1032 and MetrioPharms development pipeline, please download our corporate slide-deck: